He was previously fined for leaving a towel inside a patient. This is the fourth time in the last eight years his insurance has paid a patient.

Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...

For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...

Company remains on track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in the registrational cohort of the ADVANCED-2 trial in Q1 2026 Company expects ...

DOWNERS GROVE, IL / ACCESS Newswire / December 2, 2025 / Dr. Sarah Martin, a women's urology specialist at Duly Health and Care's Chicagoland medical group, DuPage Medical Group, Ltd., this month ...

Anktiva, also known as nogapendekin alfa inbakicept pmln, was approved in 2024 for BCG unresponsive non muscle invasive bladder cancer and it sits inside one of the most expensive corners of modern ...

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...

Adding one year of IMFINZI treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone WILMINGTON, Del.-- ...

IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial Adding one year of IMFINZI treatment ...

Risk stratification frameworks guide NMIBC management, with intermediate-risk patients requiring nuanced decision-making due to high recurrence rates. The BCG shortage has increased reliance on ...

The PIVOT-006 trial is part of a larger national effort to evaluate cretostimogene’s safety and effectiveness in bladder cancer. Bladder cancer is one of the most common urological cancers, with ...